Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants
| Autor: | Marja-Liisa Dahl, Nicolas Ansermot, Séverine Crettol, H. Uchida, Peter Riederer, Andreas Conca, E. Kim, Christoph Hiemke, S. Suzen, Margareta Reis, Olav Spigset, Oliver D. Howes, Edoardo Spina, Emmanuelle Corruble, J. de Leon, J. H. Meyer, Julia C. Stingl, Pierre Baumann, Stefan Unterecker, H. G. Ruhe, Frederik Vandenberghe, Daniel J. Müller, Gerhard Gründer, H. Mulder, Werner Steimer, Rupert Lanzenberger, B. Stegman, Christine Greiner, Rainald Moessner, Chin B. Eap |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Drug
medicine.medical_specialty precision medicine therapeutic drug monitoring media_common.quotation_subject Stress-related disorders Donders Center for Medical Neuroscience [Radboudumc 13] brain imaging Neuroimaging Psykiatri 03 medical and health sciences 0302 clinical medicine Pharmacotherapy medicine Humans Intensive care medicine Biological Psychiatry pharmacogenetics media_common Psychiatry medicine.diagnostic_test business.industry Antidepressants Precision medicine Antidepressive Agents 030227 psychiatry Psychiatry and Mental health Therapeutic drug monitoring Pharmacogenetics Drug Monitoring business |
| Zdroj: | World Journal of Biological Psychiatry, 22, 561-628 World Journal of Biological Psychiatry, 22, 8, pp. 561-628 World Journal of Biological Psychiatry Eap, C B, Gründer, G, Baumann, P, Ansermot, N, Conca, A, Corruble, E, Crettol, S, Dahl, M L, de Leon, J, Greiner, C, Howes, O, Kim, E, Lanzenberger, R, Meyer, J H, Moessner, R, Mulder, H, Müller, D J, Reis, M, Riederer, P, Ruhe, H G, Spigset, O, Spina, E, Stegman, B, Steimer, W, Stingl, J, Suzen, S, Uchida, H, Unterecker, S, Vandenberghe, F & Hiemke, C 2021, ' Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests) : focus on antidepressants ', World Journal of Biological Psychiatry, vol. 22, no. 8, pp. 561-628 . https://doi.org/10.1080/15622975.2021.1878427 |
| ISSN: | 1562-2975 |
| Popis: | Contains fulltext : 238693.pdf (Publisher’s version ) (Open Access) Objectives: More than 40 drugs are available to treat affective disorders. Individual selection of the optimal drug and dose is required to attain the highest possible efficacy and acceptable tolerability for every patient.Methods: This review, which includes more than 500 articles selected by 30 experts, combines relevant knowledge on studies investigating the pharmacokinetics, pharmacodynamics and pharmacogenetics of 33 antidepressant drugs and of 4 drugs approved for augmentation in cases of insufficient response to antidepressant monotherapy. Such studies typically measure drug concentrations in blood (i.e. therapeutic drug monitoring) and genotype relevant genetic polymorphisms of enzymes, transporters or receptors involved in drug metabolism or mechanism of action. Imaging studies, primarily positron emission tomography that relates drug concentrations in blood and radioligand binding, are considered to quantify target structure occupancy by the antidepressant drugs in vivo. Results: Evidence is given that in vivo imaging, therapeutic drug monitoring and genotyping and/or phenotyping of drug metabolising enzymes should be an integral part in the development of any new antidepressant drug.Conclusions: To guide antidepressant drug therapy in everyday practice, there are multiple indications such as uncertain adherence, polypharmacy, nonresponse and/or adverse reactions under therapeutically recommended doses, where therapeutic drug monitoring and cytochrome P450 genotyping and/or phenotyping should be applied as valid tools of precision medicine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |